475 related articles for article (PubMed ID: 29537309)
1. Pancreatic cancer subtypes: a roadmap for precision medicine.
Torres C; Grippo PJ
Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
3. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
5. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine.
Di Franco G; Usai A; Funel N; Palmeri M; Montesanti IER; Bianchini M; Gianardi D; Furbetta N; Guadagni S; Vasile E; Falcone A; Pollina LE; Raffa V; Morelli L
World J Gastroenterol; 2020 Jun; 26(21):2792-2809. PubMed ID: 32550755
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
[TBL] [Abstract][Full Text] [Related]
8. Genomics of pancreatic ductal adenocarcinoma.
Pilarsky C; Grutzmann R
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Du J; Gu J; Li J
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
[TBL] [Abstract][Full Text] [Related]
11. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
12. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
Adamska A; Falasca M
World J Gastroenterol; 2018 Aug; 24(29):3222-3238. PubMed ID: 30090003
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
14. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
15. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
16. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.
Ding D; Javed AA; Cunningham D; Teinor J; Wright M; Javed ZN; Wilt C; Parish L; Hodgin M; Ryan A; Judkins C; McIntyre K; Klein R; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Murphy A; Le DT; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; Manos L; Walsh C; Groshek L; Brown C; Yuan C; Blair AB; Groot V; Gemenetzis G; Yu J; Weiss MJ; Burkhart RA; Burns WR; He J; Cameron JL; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Hruban RH; Jaffee E; Wolfgang CL; Zheng L; Laheru DA
Cancer Lett; 2021 Jan; 497():221-228. PubMed ID: 33127389
[TBL] [Abstract][Full Text] [Related]
17. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
[TBL] [Abstract][Full Text] [Related]
18. New challenges in perioperative management of pancreatic cancer.
Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
[TBL] [Abstract][Full Text] [Related]
19. Organoid models for translational pancreatic cancer research.
Tiriac H; Plenker D; Baker LA; Tuveson DA
Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]